Below is a summary of significant updates for the NHSN Long-term Care Facility Component, which will go into effect January 1, 2021. Important: The updates are specific to the non-COVID-19 Modules. See LTCF COVID-19 Module webpage for updates related to COVID-19 surveillance and reporting for long-term care facilities.

<table>
<thead>
<tr>
<th>Impacted Module/Event</th>
<th>Summary of Modifications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthcare-associated Infection (HAI) Module: Urinary Tract Infections (UTI) Events</td>
<td>The definition of leukocytosis changed from “&gt; 14,000 cells/mm3, or Left shift (&gt; 6% or 1,500 bands/mm3)” to “[greater than 10,000 cells/mm³, or Left shift (&gt; 6% or 1,500 bands/mm³)]”</td>
</tr>
</tbody>
</table>
| HAI: UTI Pathogen Susceptibility Data Collection Forms | Changes were made to drug susceptibility data entry requirements on the UTI data collection event form.  
  - When selecting *Proteus mirabilis* as an organism, users are required to provide a susceptibility response for the following drugs: Ampicillin, Amoxicillin, Cefuroxime, Ceftriaxone, Cefixime, Ciprofloxacin, Levofloxacin, Ertapenem, Meropenem, and Imipenem.  
  - Nitrofurantoin added as a required drug for the following organisms: *E coli*, *Citrobacter* spp., *E. faecalis*, *Enterobacter* spp., *Klebsiella* spp., and *E. faecium*.  
  - Newly developed drugs have been added.  
  - Retired drugs, or drugs no longer commercially available, have been removed.  
  - Available result codes (S, I, R, NS, S-DD, N) for some drugs have been updated.  
  - Order of drugs and grouping of drugs have been updated.  
| LabID Event Module: MDRO & *C. difficile* | • The multiplier for calculating the Total CDI Rate and CDI Long-term Care Facility-onset Incidence Rate changed from 10,000 resident days to 1,000 resident-days.  
  • MDR-*Acinetobacter* definition updated to include new eligible drugs: Piperacillin/tazobactam, Cefoxitin, and Ceftriaxone.  
  • Removed Piperacillin alone as an eligible B-lactam for MDR-*Acinetobacter*.  
  • CRE: Any *Escherichia coli*, *Klebsiella oxytoca*, *Klebsiella pneumoniae*, *Klebsiella aerogenes* or *Enterobacter* spp. testing resistant to imipenem, meropenem, doripenem, ertapenem, meropenem/vaborbactam, or imipenem/relebactam by standard susceptibility testing methods |
| All Data Collection Forms | Social security number removed as an option for newly entered resident events. |
### Analysis
- Modifications made to improve consistency with variable names. For example, variables in footnotes for line listing and rate tables will auto-default to descriptive variable names.
- The “utiPlan” (UTI Plan) variable replaced “CAU Plan” variable to align with UTI reporting requirements specific to the LTCF Component.

### Vaccination
- Users will notice a Vaccination Summary option available in the left navigation bar on the NHSN LTCF Homepage to allow for easy access to reporting vaccination summary data for residents and healthcare workers.